Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | July 01, 2017 | July 06, 2017 |
| Assertio Therapeutics, IncASRT · Entity 149352 | Director | February 18, 2020 | February 19, 2020 |
| Immatics N.V.IMTX · Entity 4718 | Director | June 16, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date July 01, 2017 · Filed July 06, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 59,064 |
Reported balance
After 2017-07-01 transaction · row 1
1 source rowRow 1 · 2017-07-01 · Tax withholding · Disposed 613 · Balance 59,064 |
| Common shares without par valueSEC Table I · non-derivative | IndirectHeather L. Mason 2016 GRAT | 70,000 |
Reported balance
Holding disclosure · report date 2017-07-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 70,000 |
Assertio Therapeutics, Inc
Report date February 18, 2020 · Filed February 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,394 |
Reported balance
After 2020-02-18 transaction · row 1
1 source rowRow 1 · 2020-02-18 · Exercise / conversion · Acquired 14,394 · Balance 14,394 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2022-02-18 | Direct | 28,788 |
Reported balance
After 2020-02-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-18 · Exercise / conversion · Disposed 14,394 · Balance 28,788 F1: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock. F3: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F2: One-third of these restricted stock units are scheduled to vest on each of February 18, 2020, 2021 and 2022, assuming continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock.
F2: One-third of these restricted stock units are scheduled to vest on each of February 18, 2020, 2021 and 2022, assuming continued service through the applicable vesting date.
F3: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.
Immatics N.V.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.09 · Expires 2036-06-15 | Direct | 48,000 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 48,000 · Balance 48,000 F1: These Options vest 100% on the first anniversary of the grant date, June 16, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: These Options vest 100% on the first anniversary of the grant date, June 16, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Assertio Holdings, Inc.
Report date June 16, 2026 · Filed June 16, 2026
Section 16 reporting ended · disclosed 2026-06-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Other · Disposed 20,944 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 13, 2026, by and among Assertio Holdings, Inc. (the "Issuer"), Zydus Worldwide DMCC ("Parent"), Zara Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser") and Zydus Pharmaceuticals (USA) Inc., pursuant to which Purchaser completed a tender offer (the "Offer") for all outstanding shares of common stock of the Issuer ("Company Common Stock") at a price of $23.50 per share in cash, without interest (the "Offer Price"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"), effective as of June 16, 2026 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right [continues to Footnote 2] F2: [continues from Footnote 1] to receive the Offer Price, less any applicable withholding taxes. F3: Pursuant to the Merger Agreement, each restricted stock unit of the Issuer (each, a "Company RSU") that was outstanding but unvested immediately prior to the Effective Time became fully vested as of immediately prior to the Effective Time and, at the Effective Time, each outstanding Company RSU was cancelled and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the Offer Price. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 0 |
Reported balance
After 2026-06-16 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-06-16 · Other · Disposed 6,666 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 13, 2026, by and among Assertio Holdings, Inc. (the "Issuer"), Zydus Worldwide DMCC ("Parent"), Zara Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser") and Zydus Pharmaceuticals (USA) Inc., pursuant to which Purchaser completed a tender offer (the "Offer") for all outstanding shares of common stock of the Issuer ("Company Common Stock") at a price of $23.50 per share in cash, without interest (the "Offer Price"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"), effective as of June 16, 2026 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right [continues to Footnote 2] F2: [continues from Footnote 1] to receive the Offer Price, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.10 | Direct | 0 |
Reported balance
After 2026-06-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-16 · Disposition to issuer · Disposed 36,666 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.26 | Direct | 0 |
Reported balance
After 2026-06-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-16 · Disposition to issuer · Disposed 5,415 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 13, 2026, by and among Assertio Holdings, Inc. (the "Issuer"), Zydus Worldwide DMCC ("Parent"), Zara Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser") and Zydus Pharmaceuticals (USA) Inc., pursuant to which Purchaser completed a tender offer (the "Offer") for all outstanding shares of common stock of the Issuer ("Company Common Stock") at a price of $23.50 per share in cash, without interest (the "Offer Price"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"), effective as of June 16, 2026 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right [continues to Footnote 2]
F2: [continues from Footnote 1] to receive the Offer Price, less any applicable withholding taxes.
F3: Pursuant to the Merger Agreement, each restricted stock unit of the Issuer (each, a "Company RSU") that was outstanding but unvested immediately prior to the Effective Time became fully vested as of immediately prior to the Effective Time and, at the Effective Time, each outstanding Company RSU was cancelled and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the Offer Price.
F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 16, 2026 22:26 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,415 | Not disclosed Strike: $9.26 | Not disclosed |
DisclosureSEC source: 0001104659-26-074740 · tm2618077-3_4seq1.xml · derivative · entry 4 Mason Heather L · CIK 0001432601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,415 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof. Read SEC document |
| June 16, 2026 Filed Jun 16, 2026 22:26 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | Disposition to issuerStock Option (Right to Buy) · Derivative | 36,666 | Not disclosed Strike: $17.10 | Not disclosed |
DisclosureSEC source: 0001104659-26-074740 · tm2618077-3_4seq1.xml · derivative · entry 3 Mason Heather L · CIK 0001432601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,666 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof. Read SEC document |
| June 16, 2026 Filed Jun 16, 2026 22:26 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | OtherCommon Stock | 6,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-074740 · tm2618077-3_4seq1.xml · nonDerivative · entry 2 Mason Heather L · CIK 0001432601 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · shares: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 13, 2026, by and among Assertio Holdings, Inc. (the "Issuer"), Zydus Worldwide DMCC ("Parent"), Zara Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser") and Zydus Pharmaceuticals (USA) Inc., pursuant to which Purchaser completed a tender offer (the "Offer") for all outstanding shares of common stock of the Issuer ("Company Common Stock") at a price of $23.50 per share in cash, without interest (the "Offer Price"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"), effective as of June 16, 2026 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right [continues to Footnote 2] F2 · shares: [continues from Footnote 1] to receive the Offer Price, less any applicable withholding taxes. Read SEC document |
| June 16, 2026 Filed Jun 16, 2026 22:26 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | OtherCommon Stock | 20,944 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-074740 · tm2618077-3_4seq1.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 13, 2026, by and among Assertio Holdings, Inc. (the "Issuer"), Zydus Worldwide DMCC ("Parent"), Zara Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser") and Zydus Pharmaceuticals (USA) Inc., pursuant to which Purchaser completed a tender offer (the "Offer") for all outstanding shares of common stock of the Issuer ("Company Common Stock") at a price of $23.50 per share in cash, without interest (the "Offer Price"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"), effective as of June 16, 2026 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right [continues to Footnote 2] F2 · shares: [continues from Footnote 1] to receive the Offer Price, less any applicable withholding taxes. F3 · shares: Pursuant to the Merger Agreement, each restricted stock unit of the Issuer (each, a "Company RSU") that was outstanding but unvested immediately prior to the Effective Time became fully vested as of immediately prior to the Effective Time and, at the Effective Time, each outstanding Company RSU was cancelled and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the Offer Price. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:30 UTC | Immatics N.V. IMTX · Entity 4718 | GrantStock Option (Right to Buy) · Derivative | 48,000 | $0.00 Strike: $9.09 | $0.00 |
DisclosureSEC source: 0000950103-26-009235 · ownership.xml · derivative · entry 1 Mason Heather L · CIK 0001432601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,000 Underlying: Ordinary Shares · 48,000 shares Expires 2036-06-15 F1 · derivative.exercise_date: These Options vest 100% on the first anniversary of the grant date, June 16, 2026. Read SEC document |
| May 13, 2026 Filed May 15, 2026 22:00 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GiftCommon Stock | 6,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-062827 · tm2614833-1_4seq1.xml · nonDerivative · entry 2 Mason Heather L · CIK 0001432601 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 6,666 Read SEC document |
| May 13, 2026 Filed May 15, 2026 22:00 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GiftCommon Stock | 6,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-062827 · tm2614833-1_4seq1.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,944 Read SEC document |
| May 05, 2026 Filed May 6, 2026 22:00 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantCommon Stock | 4,851 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-056409 · tm2613761-3_4seq1.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,610 F1 · shares: Restricted stock units that (1) vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting, and (2) were granted on the date of the Issuer's 2026 Annual Meeting of Stockholders in accordance with the Issuer's Nonemployee Director Compensation & Grant Policy. F2 · balance_after: On December 26, 2025, the Issuer effected a 1-for-15 reverse stock split (the "Reverse Stock Split"). The number of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| May 07, 2025 Filed May 9, 2025 22:00 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantStock Option (right to buy) · Derivative | 81,225 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001104659-25-046865 · tm2514518-3_4seq1.xml · derivative · entry 2 Mason Heather L · CIK 0001432601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,225 Underlying: Common Stock · 81,225 shares Expires 2035-05-07 F3 · price: These derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for these derivative securities. F2 · derivative.exercise_date: Stock Options that (1) vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting, and (2) were granted on the date of the Issuer's 2025 Annual Meeting of Stockholders in accordance with the Issuer's Nonemployee Director Compensation & Grant Policy. Read SEC document |
| May 07, 2025 Filed May 9, 2025 22:00 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantCommon Stock | 53,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-046865 · tm2514518-3_4seq1.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 341,400 F1 · shares: Restricted stock units that (1) vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting, and (2) were granted on the date of the Issuer's 2025 Annual Meeting of Stockholders in accordance with the Issuer's Nonemployee Director Compensation & Grant Policy. Read SEC document |
| November 18, 2024 Filed Nov 19, 2024 14:02 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | PurchaseCommon Stock | 75,000 | $0.80 | $60,000.00 |
DisclosureSEC source: 0001104659-24-120396 · tm2428856-1_4seq1.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 287,650 Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 22:00 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | PurchaseCommon Stock | 25,000 | $0.97 | $24,250.00 |
DisclosureSEC source: 0001104659-24-069165 · tm2416650-1_4seq1.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Director · Interim Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,650 Read SEC document |
| January 02, 2024 Filed Jan 5, 2024 01:00 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantStock Option (Right to Buy) · Derivative | 550,000 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001104659-24-001488 · tm241926-1_4seq1.xml · derivative · entry 1 Mason Heather L · CIK 0001432601 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 550,000 shares Expires 2034-01-02 F2 · price: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F1 · derivative.exercise_date: The stock option vests (a) as to 50% in 12 equal monthly installments following January 2, 2024, subject to the reporting person's continued service to the registrant through each applicable vesting date, and (b) as to 50% upon the date a permanent Chief Executive Officer who is hired during the reporting person's service as interim CEO commences employment with the registrant and remains employed for a period of 30 days. Read SEC document |
| May 19, 2023 Filed May 23, 2023 00:00 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | SaleCommon Stock | 89,286 | $7.30 | $652,011.02 |
DisclosureSEC source: 0001104659-23-063278 · tm2316458-1_4seq1.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,650 F1 · price: The price reported is a weighted average sale price. The shares were sold in multiple same-way transactions on May 19, 2023 at prices ranging from $7.30 to $7.32 per share of common stock. If requested by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, the reporting person will provide full information regarding the number of shares of common stock sold at each separate price. Read SEC document |
| May 10, 2023 Filed May 12, 2023 22:34 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantStock Option (right to buy) · Derivative | 3,821 | $0.00 Strike: $7.55 | $0.00 |
DisclosureSEC source: 0001808665-23-000036 · wf-form4_168393088462744.xml · derivative · entry 2 Mason Heather L · CIK 0001432601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,821 Underlying: Common Stock · 3,821 shares Expires 2033-05-10 F3 · price: These derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for these derivative securities. F2 · derivative.exercise_date: Stock Options that vest in full on the first anniversary of the grant date and which were granted on the date of the Issuer's 2023 Annual Meeting of Stockholders in accordance with the Issuer's Nonemployee Director Compensation & Grant Policy. Read SEC document |
| May 10, 2023 Filed May 12, 2023 22:34 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantCommon Stock | 31,194 | $0.00 | $0.00 |
DisclosureSEC source: 0001808665-23-000036 · wf-form4_168393088462744.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,936 F1 · shares: Restricted stock units that vest in full on the first anniversary of the grant date and which were granted on the date of the Issuer's 2023 Annual Meeting of Stockholders in accordance with the Issuer's Nonemployee Director Compensation & Grant Policy. Read SEC document |
| May 04, 2022 Filed May 7, 2022 00:10 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantCommon Stock | 86,286 | $0.00 | $0.00 |
DisclosureSEC source: 0001432601-22-000002 · wf-form4_165188223779368.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,741 F1 · shares: Restricted stock units that vest in full on the first anniversary of the grant date and which were granted on the date of the Issuer's 2022 Annual Meeting of Stockholders in accordance with the Issuer's Nonemployee Director Compensation & Grant Policy. Read SEC document |
| February 18, 2022 Filed Feb 18, 2022 22:44 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | Exercise / conversionRestricted Stock Units · Derivative | 3,598 | $0.00 | $0.00 |
DisclosureSEC source: 0001432601-22-000001 · wf-form4_164522426758587.xml · derivative · entry 2 Mason Heather L · CIK 0001432601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,598 shares Expires 2022-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the registrant's common stock. F4 · price: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F3 · derivative.exercise_date: One-third of these restricted stock units are scheduled to vest on each of February 18, 2020, 2021 and 2022, assuming continued service through the applicable vesting date. Read SEC document |
| February 18, 2022 Filed Feb 18, 2022 22:44 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | Exercise / conversionCommon Stock | 3,598 | $0.00 | $0.00 |
DisclosureSEC source: 0001432601-22-000001 · wf-form4_164522426758587.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: On May 18, 2021 the Issuer effected a 1-for-4 reverse stock split (the "Reverse Stock Split"). The number of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| May 11, 2021 Filed May 13, 2021 21:25 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantCommon Stock | 357,143 | $0.00 | $0.00 |
DisclosureSEC source: 0001808665-21-000044 · wf-form4_162094112354297.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 623,431 F1 · shares: Restricted stock units that vest in full on the first anniversary of the grant date. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 22:28 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | Exercise / conversionRestricted Stock Units · Derivative | 14,394 | $0.00 | $0.00 |
DisclosureSEC source: 0001808665-21-000008 · wf-form4_161403290001911.xml · derivative · entry 2 Mason Heather L · CIK 0001432601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,394 Underlying: Common Stock · 14,394 shares Expires 2022-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock. F3 · price: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F2 · derivative.exercise_date: One-third of these restricted stock units are scheduled to vest on each of February 18, 2020, 2021 and 2022, assuming continued service through the applicable vesting date. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 22:28 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | Exercise / conversionCommon Stock | 14,394 | $0.00 | $0.00 |
DisclosureSEC source: 0001808665-21-000008 · wf-form4_161403290001911.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2020 Filed May 22, 2020 01:04 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantCommon Stock | 237,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001808665-20-000008 · wf-form4_159010943855329.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,894 F1 · date: As a result of a holding company reorganization effective May 19, 2020, Assertio Holdings, Inc., is the successor issuer to Assertio Therapeutics, Inc., pursuant to 12g-3(a) of the Exchange Act. F2 · shares: Restricted stock units that vest in full on the first anniversary of the grant date. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:00 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | Exercise / conversionRestricted Stock Units · Derivative | 14,394 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001005201-20-000016 · wf-form4_158214958426393.xml · derivative · entry 2 Mason Heather L · CIK 0001432601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,788 Underlying: Common Stock · 14,394 shares Expires 2022-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock. F3 · price: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F2 · derivative.exercise_date: One-third of these restricted stock units are scheduled to vest on each of February 18, 2020, 2021 and 2022, assuming continued service through the applicable vesting date. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:00 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | Exercise / conversionCommon Stock | 14,394 | $0.00 | $0.00 |
DisclosureSEC source: 0001005201-20-000016 · wf-form4_158214958426393.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2019 Filed Feb 19, 2019 21:29 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | GrantRestricted Stock Units · Derivative | 43,182 | $0.00 | $0.00 |
DisclosureSEC source: 0001005201-19-000033 · wf-form4_155061176028655.xml · derivative · entry 1 Mason Heather L · CIK 0001432601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,182 Underlying: Common Stock · 43,182 shares Expires not disclosed F1 · security: Grant of restricted stock unit awards pursuant to the Company's Non-Employee Director Compensation and Grant Policy. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the registrant's common stock. F4 · price: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F3 · derivative.exercise_date: One-third of these restricted stock units are scheduled to vest on each of February 18, 2020, 2021 and 2022, assuming continued service through the applicable vesting date. F3 · derivative.expiration_date: One-third of these restricted stock units are scheduled to vest on each of February 18, 2020, 2021 and 2022, assuming continued service through the applicable vesting date. Read SEC document |
| July 01, 2017 Filed Jul 6, 2017 00:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 613 | $48.61 | $29,797.93 |
DisclosureSEC source: 0001179110-17-010133 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,064 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $45.01 | $4,501.01 |
DisclosureSEC source: 0001179110-17-003666 · edgar.xml · nonDerivative · entry 4 Mason Heather L · CIK 0001432601 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,677 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 134 | $45.01 | $6,031.47 |
DisclosureSEC source: 0001179110-17-003666 · edgar.xml · nonDerivative · entry 3 Mason Heather L · CIK 0001432601 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,777 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,678 | $45.02 | $75,535.17 |
DisclosureSEC source: 0001179110-17-003666 · edgar.xml · nonDerivative · entry 2 Mason Heather L · CIK 0001432601 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,911 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,530 | $45.46 | $387,773.80 |
DisclosureSEC source: 0001179110-17-003666 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,589 Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 38,940 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-17-002933 · edgar.xml · derivative · entry 3 Mason Heather L · CIK 0001432601 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,940 Underlying: Common shares · 38,940 shares Expires 2027-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,980 on 02/17/2018, 12,980 on 02/17/2019, and 12,980 on 02/17/2020. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 5,630 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002933 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,119 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 22:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 35,700 | $0.00 Strike: $25.25 | $0.00 |
DisclosureSEC source: 0001179110-17-001517 · edgar.xml · derivative · entry 4 Mason Heather L · CIK 0001432601 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 35,700 shares Expires 2017-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 22:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 35,700 | $40.77 | $1,455,489.00 |
DisclosureSEC source: 0001179110-17-001517 · edgar.xml · nonDerivative · entry 2 Mason Heather L · CIK 0001432601 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,489 Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 22:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 35,700 | $25.25 | $901,285.77 |
DisclosureSEC source: 0001179110-17-001517 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2016 Filed Jul 6, 2016 21:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 613 | $39.31 | $24,097.03 |
DisclosureSEC source: 0001179110-16-027478 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,489 Read SEC document |
| February 29, 2016 Filed Mar 2, 2016 23:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,432 | $39.27 | $56,227.48 |
DisclosureSEC source: 0001179110-16-020730 · edgar.xml · nonDerivative · entry 3 Mason Heather L · CIK 0001432601 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,102 Read SEC document |
| February 29, 2016 Filed Mar 2, 2016 23:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,600 | $39.27 | $62,827.20 |
DisclosureSEC source: 0001179110-16-020730 · edgar.xml · nonDerivative · entry 2 Mason Heather L · CIK 0001432601 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,534 Read SEC document |
| February 29, 2016 Filed Mar 2, 2016 23:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 7,155 | $39.52 | $282,765.60 |
DisclosureSEC source: 0001179110-16-020730 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,134 Read SEC document |
| February 19, 2016 Filed Feb 23, 2016 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 214,041 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-16-019900 · edgar.xml · derivative · entry 2 Mason Heather L · CIK 0001432601 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,041 Underlying: Common shares · 214,041 shares Expires 2026-02-18 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 71,347 on 02/19/2017, 71,347 on 02/19/2018, and 71,347 on 02/19/2019. Read SEC document |
| February 19, 2016 Filed Feb 23, 2016 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 24,414 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-019900 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,289 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| July 01, 2015 Filed Jul 2, 2015 21:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 614 | $49.08 | $30,135.12 |
DisclosureSEC source: 0001179110-15-010822 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,875 Read SEC document |
| April 27, 2015 Filed Apr 29, 2015 22:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,695 | $47.46 | $127,891.23 |
DisclosureSEC source: 0001179110-15-006831 · edgar.xml · nonDerivative · entry 3 Mason Heather L · CIK 0001432601 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,489 Read SEC document |
| April 27, 2015 Filed Apr 29, 2015 22:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 10,705 | $47.45 | $507,962.96 |
DisclosureSEC source: 0001179110-15-006831 · edgar.xml · nonDerivative · entry 2 Mason Heather L · CIK 0001432601 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,184 Read SEC document |
| April 27, 2015 Filed Apr 29, 2015 22:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $47.45 | $4,745.00 |
DisclosureSEC source: 0001179110-15-006831 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,889 Read SEC document |
| February 27, 2015 Filed Mar 3, 2015 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,721 | $47.61 | $415,206.81 |
DisclosureSEC source: 0001179110-15-004026 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,989 Read SEC document |
| February 20, 2015 Filed Feb 24, 2015 22:37 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 149,925 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003323 · edgar.xml · derivative · entry 2 Mason Heather L · CIK 0001432601 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,925 Underlying: Common shares · 149,925 shares Expires 2025-02-19 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 49,975 on 2/20/16, 49,975 on 2/20/17, and 49,975 on 2/20/18. Read SEC document |
| February 20, 2015 Filed Feb 24, 2015 22:37 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 21,276 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003323 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,710 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| July 01, 2014 Filed Jul 3, 2014 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 24,634 | $0.00 Strike: $41.14 | $0.00 |
DisclosureSEC source: 0001179110-14-011502 · edgar.xml · derivative · entry 2 Mason Heather L · CIK 0001432601 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,634 Underlying: Common shares · 24,634 shares Expires 2024-06-30 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,212 on 7/1/2015, 8,211 on 7/1/2016, and 8,211 on 7/1/2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.